Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

CBST 65.60 +0.80 (1.23%)
price chart
Cubist Pharmaceuticals: Ripe For Acquisition?
Threats from the increase in drug-resistant germs, and the subsequent rise in demand for more effective and high-impact antibiotics has spurred interest in companies such as Cubist Pharmaceuticals Inc (CBST). The Massachusetts-based drug developer has ...
Cubist Pharmaceuticals Lowered to "Underperform" at Zacks (CBST)  Watch List News (press release)
Cubist Pharmaceuticals Director Sells $585000 in Stock (CBST)  Mideast Time
Related articles »  
Cubist Recalls Its Lifesaving Drug Cubicin
Cubist Pharmaceuticals Inc (CBST) announced yesterday, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug.
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Nine Lots of ...  MarketWatch
Cubist Pharma Recalls Some Vials of Antibiotic Cubicin  Medscape
Related articles »  
Cubist Pharmaceuticals Rating Lowered to Underperform at Zacks (CBST)
Cubist Pharmaceuticals Inc logo Zacks cut shares of Cubist Pharmaceuticals (NASDAQ:CBST) from a neutral rating to an underperform rating in a research note issued to investors on Monday.
Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma ...
Further, Cubist Pharmaceuticals Inc.'s shares have plummeted 11.93% over the last one month and 12.24% over the past three months.
Related articles »  
Cubist Pharmaceuticals SVP Gregory Stea Sells 38326 Shares (CBST)
One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company's stock. Cubist Pharmaceuticals currently has a consensus rating of �Buy� and an average price target of $79.64.
Related articles »  
Insider Selling: Cubist Pharmaceuticals COO Unloads 1003 Shares of Stock ...
Cubist Pharmaceuticals has a one year low of $58.50 and a one year high of $82.12. The stock has a 50-day moving average of $64.44 and a 200-day moving average of $69.36.
Active Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lumos Networks ...
Cubist Pharmaceuticals (NASDAQ:CBST) has been given an average rating of �Buy� by the fourteen brokerages that are currently covering the company. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy ...
Best Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Electronics for ...
FDA is reporting that Cubist Pharmaceuticals Inc. (NASDAQ:CBST) on 8 August has announced it is voluntarily recalling certain lots of CUBICIN (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in ...
Cubist Pharmaceuticals Inc.: Cubist Reports Second Quarter 2014 Financial ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014.
Cubist Pharmaceuticals Q2 14 Earnings Conference Call At 5:00 PM ET  NASDAQ
Cubist Reports Second Quarter 2014 Financial Results  Wall Street Journal
Related articles »  
Mid Cap Stocks Landing in the Bullish Zone: Cubist Pharmaceuticals Inc (CBST ...
Cubist Pharmaceuticals Inc (NASDAQ:CBST) percentage change flew +2.57% to close at $66.22 with the total traded volume of 884,374.00 shares more than average volume of 804,897.00.